H5N1 Vaccine Study in Japanese Adults

A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years

The purpose of this study is to obtain immunogenicity and safety data of two different dose levels of an H5N1 pandemic influenza vaccine in a healthy Japanese adult population aged 18 to 59 years.

Study Overview

• Status: Completed
• Conditions: H5N1 Influenza
• Intervention / Treatment: Biological: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)

• Study Type: Interventional
• Enrollment (Actual): 340
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Japan
  • Fukuoka-Ken
    • Fukuoka-shi, Fukuoka-Ken, Japan, 812-0025
      • Medical Co. LTA PS Clinic
  • Kagoshima-Ken
    • Kagoshima-shi, Kagoshima-Ken, Japan, 890-0081
      • CPC Clinic, Medipolis Medical Research Institute
  • Osaka-Fu
    • Osaka-shi, Osaka-Fu, Japan, 532-0003
      • Osaka Pharmacology Clinical Research Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 59 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is 18 to 59 years old at the time of screening
• Subject is generally healthy, as determined by the investigator´s clinical judgement through collection of medical history and performance of a physical examination
• Subject is physically and mentally capable of participating in the study and willing to adhere to study procedures to include completion of all elements of the study diary
• If female of childbearing potential, subject presents with a negative urine pregnancy test result within 24 hours prior ot the scheduled first vaccination and agrees to employ adequate birth control measures for the duration of the study

Exclusion Criteria:

• Subject has a history of infectin with H5N1 virus or a history of vaccination with an H5N1 influenza vaccine
• Subject is at high risk of contracting H5N1 influenza infection (e.g. poultry workers)
• Subject currently has or has a history of a significant cardiovascular (including hypertension), respiratory (including asthma), metabolic, neurological (including Guillain-Barré Syndrome and acute disseminated encephalomyelitis), hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder
• Subject has any inherited or acquired immunodeficiency
• Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to: systemic or inhaled corticosteroids, radiation treatment, or other immunosuppressive or cytotoxic drugs
• Subject has a history of severe allergic reactions or anaphylaxis
• Subject has a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating
• Subject has received a blood transfusion or immunoglobulins within 90 days prior to study entry
• Subject has donated blood or plasma within 30 days prior to study entry
• Subject has received any influenza or any live vaccine within 4 weeks or any other inactivated vaccine within 2 weeks prior to vaccination in this study
• Subject has a functional or surgical asplenia
• Subject has a known or suspected problem with alcohol or drug abuse
• Subject was administered an investigational drug within 6 weeks prior to study entry or is concurrently participating in a clinical study that includes the administration of an investigational product
• Subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator/subinvestigator or site personnel conducting the study
• If female, subject is pregnant or lactating at the time of enrollment
• Subject has any other condition that disqualifies his/her participation in the study in the opinion of the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment group I / Intramuscular; 85 subjects to receive 2 intramuscular vaccinations at Dose A on Days 1 and 22	Biological: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated); Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
Experimental: Treatment group II / Intramuscular; 85 subjects to receive 2 intramuscular vaccinations at Dose B on Days 1 and 22	Biological: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated); Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
Experimental: Treatment group III / Subcutaneous; 85 subjects to receive 2 subcutaneous vaccinations at Dose A on Days 1 and 22	Biological: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated); Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
Experimental: Treatment group IV / Subcutaneous; 85 subjects to receive 2 subcutaneous vaccinations at Dose B on Days 1 and 22	Biological: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated); Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects with antibody response to the vaccine strain	Measurement by single radial hemolysis (SRH) assay	21 days after 2nd vaccination
Number of subjects demonstrating seroconversion	Measurement by SRH assay	21 days after 2nd vaccination
Fold increase of antibody response	Measurement by SRH assay	21 days after 2nd vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects with antibody response to the vaccine strain	Measurement by SRH (except at 21 days after 2nd vaccination), microneutralization (MN) and hemagglutination inhibition (HI) assay	21 days after 1st and 21+180 days after 2nd vaccination
Number of subjects demonstrating seroconversion	Measurement by SRH (except at 21 days after 2nd vaccination), MN and HI assay	21 days after 1st and 21+180 days after 2nd vaccination
Antibody response	Measurement by SRH, MN and HI assay	21 days after 1st and 21 + 180 days after 2nd vaccination
Fold increase of antibody response	Measurement by SRH (except at 21 days after 2nd vaccination), MN and HI assay	21 days after 1st and 21+180 days after 2nd vaccination as compared to baseline

Collaborators and Investigators

• Sponsor: Ology Bioservices
• Collaborators: Baxter Innovations GmbH
• Investigators: Study Director: Alexander Geisberger, MD, Baxter Innovations GmbH

Study record dates

Study Major Dates

• Study Start: June 1, 2011
• Primary Completion (Actual): August 1, 2011
• Study Completion (Actual): May 1, 2012

Study Registration Dates

• First Submitted: June 24, 2011
• First Submitted That Met QC Criteria: June 24, 2011
• First Posted (Estimate): June 27, 2011

Study Record Updates

• Last Update Posted (Estimate): October 9, 2015
• Last Update Submitted That Met QC Criteria: October 7, 2015
• Last Verified: September 1, 2012

More Information

Terms related to this study

• Keywords: Prophylaxis of influenza infection caused by a pandemic influenza virus (H5N1)
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human; Influenza in Birds
• Other Study ID Numbers: 811001